Current strategies designed to interfere with PD-1/PD-L1 signaling through the use of humanized monoclonal antibodies (e.g. Nivolumab) have shown robust clinical responses in patients with heavily-pre-treated advanced cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. The gene discussed is CD274; the disease is melanoma.